Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21619357 | 0.88 | CMA1 (0.51) | TGM2CES1KMT2AMEN1CMA1 | |
| SCHEMBL22278373 | 0.82 | CMA1 (0.56) | TGM2CES1KMT2AMEN1CMA1 | |
| SCHEMBL1119397 | 0.82 | CMA1 (0.56) | TGM2CES1KMT2AMEN1CMA1 | |
| SCHEMBL2605640 | 0.79 | TGM2 (0.56) | TGM2CES1KMT2AMEN1CMA1 | |
| SCHEMBL14553936 | 0.79 | PDE3B (0.39) | TGM2CES1KMT2AMEN1GSK3B | |
| SCHEMBL7332800 | 0.79 | TGM2 (0.56) | TGM2CES1KMT2AMEN1CCNB2 | |
| SCHEMBL26820457 | 0.79 | PARP1 (0.47) | KMT2AMEN1PARP10PARP1CCNB2 | |
| SCHEMBL30972546 | 0.79 | TGM2 (0.77) | TGM2CES1KMT2AMEN1CCNB2 | |
| SCHEMBL24665688 | 0.77 | TGM2 (0.68) | TGM2CES1KMT2AMEN1CCNB2 | |
| SCHEMBL23615507 | 0.77 | TGM2 (0.52) | TGM2CES1KMT2AMEN1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3101013-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3098218-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3088395-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3085694-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3085696-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-20070004707-A1 | [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | RAMAMOORTHY P S | 2007-01-04 | — | — | US | disclosed |
| US-7129237-B2 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1497293-A1 | (1,4)DIAZEPINO(6,7,1-IJ)QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS | Wyeth (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1027042-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040009970-A1 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH | 2004-01-15 | — | — | US | disclosed |
| WO-2003091250-A1 | [1,4]DIAZEPINO[6,7,1-IJ]QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS | WYETH (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6458783-B1 | INHIBITION OF FARNESYL TRANSFERASE, WHICH IS AN ENZYME INVOLVED IN RAS ONCOGENE EXPRESSION, IS EFFECTED BY COMPOUNDS OF THE FORMULAS OF BENODIAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-01 | — | — | US | disclosed |
| WO-2001081322-A1 | NON-IMIDAZOLE BENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1027042-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999018951-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004707-A1 | [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR1D | TGM2 3843/4885CES1 635/4885KMT2A 471/4885 |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | TGM2 3653/4885CES1 3656/4885KMT2A 2455/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | TGM2 3653/4885CES1 3656/4885KMT2A 2455/4885 |
| US-20040009970-A1 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR1D | TGM2 3595/4885CES1 675/4885KMT2A 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.